MedPath

Eseba-vec Plus Pembrolizumab Shows Promise in HPV16-Positive Head and Neck Cancer

• A phase II trial evaluated eseba-vec, an HPV16-targeted immunotherapeutic agent, combined with pembrolizumab as a first-line treatment for HPV16-positive relapsed or metastatic head and neck squamous cell carcinoma. • The combination therapy demonstrated an overall response rate of 52% in patients with PD-L1 CPS ≥ 20, with a disease control rate of 80% as of the September 2024 data cutoff. • Preliminary median progression-free survival exceeded 16 months, and the 12-month overall survival rate was 83%, with 66.7% of confirmed responses ongoing. • The observed clinical activity is supported by a rapid and durable tumor antigen–specific T-cell response, with a manageable safety profile.

A novel combination of eseba-vec and pembrolizumab is showing promising results in patients with HPV16-positive relapsed or metastatic head and neck squamous cell carcinoma. The phase II trial results, presented at the 2024 Society for Immunotherapy in Cancer (SITC) Annual Meeting, indicate a clinically meaningful response rate and encouraging progression-free and overall survival data.
The study focused on a subset of 27 patients with PD-L1 combined positive score (CPS) ≥ 20, with 25 patients evaluable for response. The data revealed an overall response rate of 52% for all eseba-vec doses tested, and a disease control rate of 80%, as of the September 2024 data cutoff. Preliminary median progression-free survival is more than 16 months, with a 12-month overall survival rate of 83%. Furthermore, 66.7% of confirmed responses are ongoing.

Durable T-Cell Response

Investigators reported that the observed clinical activity is supported by a rapid and durable tumor antigen–specific T-cell response. Data are generally consistent for the selected phase III dose level, including a 55% overall response rate, which is an approximately twofold increase compared with historical pembrolizumab monotherapy data. Serious treatment-related adverse events occurred in 7.6% of patients.

Expert Commentary

"As a medical oncologist who specializes in head and neck cancers, I am inspired by the results of the expanded eseba-vec/pembrolizumab phase II study because of the potentially clinically meaningful response rate and encouraging [progression-free survival and overall survival] data," said Alan Ho, MD, PhD, Chief of the Head and Neck Oncology Service at Memorial Sloan Kettering Cancer Center. "In addition, the regimen has a manageable safety profile that ensures most patients can maintain treatment."
The study suggests that the combination of eseba-vec and pembrolizumab could offer a significant improvement in outcomes for patients with HPV16-positive relapsed or metastatic head and neck squamous cell carcinoma, particularly those with high PD-L1 expression.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Perioperative Toripalimab Improves Outcomes in Nasopharyngeal Carcinoma

A phase II trial showed that perioperative toripalimab combined with chemoradiotherapy significantly improved 2-year progression-free survival in patients with high-risk, advanced nasopharyngeal carcinoma.
The 2-year progression-free survival rate was 92.0% in the toripalimab group compared to 74.0% in the control group (HR = 0.40, P = .019).

Immunotherapy Advances in Head and Neck Cancer Treatment Highlighted

Pembrolizumab has been approved as a first-line treatment for recurrent and metastatic head and neck squamous cell carcinoma (HNSCC), with or without chemotherapy, based on PD-L1 expression.
Clinical trials are necessary to refine biomarker-driven protocols and standardize pathological methods for combined immunotherapy regimens in HNSCC.

Pembrolizumab Plus Chemoradiotherapy Significantly Improves Survival in High-Risk Cervical Cancer

The KEYNOTE-A18 trial demonstrated a significant overall survival (OS) benefit with pembrolizumab plus chemoradiotherapy in high-risk, locally advanced cervical cancer patients.
At 36 months, the OS rate was 82.6% in the pembrolizumab arm compared to 74.8% in the chemoradiotherapy-only arm, indicating a clinically meaningful improvement.

Versamune HPV Vaccine Plus Pembrolizumab Shows Promise in HPV16+ Head and Neck Cancer

The addition of Versamune HPV (PDS0101) to pembrolizumab demonstrated robust and durable responses in first-line treatment for HPV16-positive recurrent or metastatic HNSCC.
In the VERSATILE-002 trial, the combination therapy achieved a median overall survival of 30 months and an objective response rate of 35.8% in patients with a CPS ≥ 1.

PDS Biotech's Versamune® HPV Shows Promising Results in Head and Neck Cancer Trial

Updated data from the VERSATILE-002 trial shows Versamune® HPV combined with pembrolizumab demonstrates a median overall survival of 30 months in HPV16-positive recurrent/metastatic HNSCC patients.
The combination therapy achieved an objective response rate of 36% and a disease control rate of 77% in the first-line treatment of HNSCC.

PDS Biotech's Versamune HPV Plus Keytruda Shows Promising Results in HPV16-Positive Head and Neck Cancer

Updated data from the VERSATILE-002 Phase 2 study reveals a 36% objective response rate in HNSCC patients treated with Versamune HPV plus Keytruda.
The study also demonstrated a 77% disease control rate and a median overall survival rate of 20% in the treated HNSCC patient population.

PDS Biotech's Versamune HPV Plus Pembrolizumab Shows Promising Survival in Head and Neck Cancer

PDS Biotechnology's Versamune HPV, combined with pembrolizumab, demonstrates a median overall survival of 30 months in HPV16-positive recurrent/metastatic HNSCC patients.
The combination therapy achieved an objective response rate of 36% and a disease control rate of 77% in the VERSATILE-002 Phase 2 trial.

PDS Biotech's Versamune-HPV and Keytruda Combo Shows Promising Survival in Head and Neck Cancer

PDS Biotechnology's Versamune-HPV, combined with Keytruda, demonstrated a median overall survival of 30 months in HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).
The combination therapy achieved an objective response rate of 36%, surpassing the published rates of 19-25% for pembrolizumab alone in similar patient populations.

PDS Biotech's Versamune® HPV Plus Pembrolizumab Shows Promising Results in HPV16-Positive Head and Neck Cancer

Updated data from the VERSATILE-002 trial shows a median overall survival of 30 months in patients treated with Versamune® HPV plus pembrolizumab.
The combination therapy achieved an objective response rate of 36% and a disease control rate of 77% in patients with HPV16-positive recurrent/metastatic HNSCC.

FDA Approves New First-Line Treatment for Head and Neck Cancers

The FDA has approved a new first-line treatment for metastatic or recurrent head and neck cancer, using the immunotherapy drug pembrolizumab, either alone or with chemotherapy. This treatment, developed through research led by Yale's Dr. Barbara A. Burtness, significantly improves survival rates and is less toxic than previous treatments.

Reference News

[1]
Novel Combination Studied in HPV16-Positive Relapsed or Metastatic Head and Neck ...
ascopost.com · Dec 9, 2024

Alan Ho, MD, PhD, presented updated phase II trial results of HPV16-targeted immunotherapeutic agent eseba-vec and PD-1 ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy